Silo Pharma announces important milestone. Investigator led study using Psilocybin to treat Parkinson’s disease has been submitted for ethics board review.
13 mai 2021 08h15 HE
|
Silo Pharma, Inc.
Englewood Cliffs, NJ, May 13, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...
Silo Pharma (SILO) and Zylo Therapeutics, Inc. (ZTI) enter into Joint Venture Agreement to focus on the development of ketamine using ZTI’s Z-pod™ technology for the transdermal time released delivery of therapeutics
28 avr. 2021 08h05 HE
|
Silo Pharma, Inc.
Englewood Cliffs, NJ, April 28, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...
Silo Pharma (SILO) Announces Plans to Uplist to the NASDAQ
22 avr. 2021 08h05 HE
|
Silo Pharma, Inc.
Englewood Cliffs, NJ, April 22, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today...
Silo Pharma Finalizes Sublicense Deal for its Targeted Psilocybin Cancer Therapeutic Technology
07 avr. 2021 08h01 HE
|
Silo Pharma, Inc.
Agreement to explore the use of Silo Pharma’s Novel Peptide Englewood Cliffs, NJ, April 07, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company...
Silo Pharma, Inc. Enters into an Exclusive Option Agreement with the University of Maryland, Baltimore for patented Homing Peptides Targeting Rheumatoid Arthritis
04 mars 2021 08h44 HE
|
Silo Pharma, Inc.
Englewood Cliffs NJ, March 04, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTC QB: SILO), a developmental stage biopharmaceutical company, today announced that it has executed an exclusive option...
Silo Pharma to Present at Proactive's One2One Virtual Investor Forum
23 févr. 2021 08h15 HE
|
Silo Pharma, Inc.
Englewood Cliffs, NJ, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic...
Silo Pharma Licenses Novel Peptide-Guided Drug Delivery Approach for the Treatment of MS
18 févr. 2021 08h15 HE
|
Silo Pharma, Inc.
Englewood Cliffs, NJ, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic...
Silo Pharma Announces Private Placement of Equity Definitive Agreement for $4.275 Million in Gross Proceeds
10 févr. 2021 08h45 HE
|
Silo Pharma, Inc.
Silo Pharma to pursue additional strategic partnerships and intellectual property acquisitions in the psychedelic medicine space Englewood Cliffs, NJ, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Silo...
Silo Pharma Reaches Terms with University of Maryland Baltimore for Exclusive License of Central Nervous Homing Peptide for Neuroinflammatory Disease
26 janv. 2021 08h18 HE
|
Silo Pharma, Inc.
Englewood Cliffs, NJ, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic...
Silo Pharma to Participate in Virtual Conference on Investing in Psychedelics
19 janv. 2021 08h13 HE
|
Silo Pharma, Inc.
NEW JERSEY , Jan. 19, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research...